Results 251 to 260 of about 29,662,057 (278)

Sodium-glucose co-transporter 2 inhibitors: evidence and place in therapy

Expert Review of Endocrinology & Metabolism, 2015
Type 2 diabetes effects millions of people yet remains difficult to treat with oral pharmacotherapy. Metformin is the first line recommended therapy, and current guidelines suggest individualized therapy for second line selection. Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are the newest class of agents in treating type 2 diabetes via an ...
Molly G, Minze, Robin L, Koffarnus, Trista A, Bailey, Sandy, Diec, Krystal L, Edwards   +4 more
openaire   +2 more sources

Sodium Glucose Co-Transporter 2 Inhibitors: Beyond Glucose Lowering

Current Drug Targets, 2018
Diabetes is an important cause of morbidity and mortality worldwide. Management of blood glucose is critical for diabetic patients since diabetes carries a risk for many diseases and disorders. Although there are several antidiabetic agents in the markets for a long time, some of the agents have dose-limiting side effects, such as hypoglycemia and ...
Ceylan, Asli F., Ren, Sidney Y.
openaire   +3 more sources

Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes

Expert Opinion on Emerging Drugs, 2013
Type 2 diabetes mellitus (T2DM) is a public health challenge globally. Numerous treatments are available which can improve insulin sensitivity or stimulate its secretion including biguanides, sulphonylureas and glitazones, as well as insulin, GLP-1 agonists and DPP-IV inhibitors.
Luke D, Boyle, John P H, Wilding
openaire   +2 more sources

Sodium-Glucose Co-Transport Inhibitors

Drugs, 2010
The kidney plays a major role in glucose homeostasis because of its role in gluconeogenesis and the glomerular filtration and reabsorption of glucose in the proximal convoluted tubules. Approximately 180 g of glucose is filtered daily in the glomeruli of a normal healthy adult. Typically, all of this glucose is reabsorbed with
Joshua J, Neumiller, John R, White, R Keith, Campbell   +2 more
openaire   +2 more sources

[Sodium-glucose co-transporter 2 inhibitor for diabetes?].

Nederlands tijdschrift voor geneeskunde, 2016
Following initial expectations, raised by the results of the United Kingdom Prospective Diabetes Study, intervention studies aimed at tight glucose control did not reduce cardiovascular disease. The EMPA-REG OUTCOME, an empagliflozin intervention study in over 7,000 patients with type 2 diabetes mellitus and a history of cardiovascular disease, for the
openaire   +1 more source

A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors

Cell Metabolism, 2021
Hiddo J L Heerspink, Taha Sen
exaly  

Comment on Sodium-Glucose Co-Transporter 2 Inhibitors and Heart Failure

The American Journal of Cardiology, 2020
Erkan Cure, Medine Cumhur Cure
openaire   +2 more sources

Effect of sodium-glucose co-transporter 2 inhibitors on hepatic parameters: A systematic review and meta-analysis of randomized controlled trials

Pharmacological Research, 2021
Luis E Simental-Mendía, Adriana Sánchez-García, Mario Simental-Mendía   +2 more
exaly  

Potential drug-drug interaction between sodium-glucose co-transporter 2 inhibitors and statins: pharmacological and clinical evidence

Expert Opinion on Drug Metabolism and Toxicology, 2021
Christos Kontogiorgis, Georgios Poulentzas, Antonios Douros   +2 more
exaly  

Cardiac, renal, and metabolic effects of sodium–glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium–glucose co-transporter 2 inhibitors

European Journal of Heart Failure, 2021
Nikolaus Marx, Gianluigi Savarese, Marija Polovina   +2 more
exaly